BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 15, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Onglyza saxagliptin: Phase III data

A 24-week, double-blind, international Phase III trial in 565 patients with Type II diabetes receiving thiazolidinedione (TZD) showed that Onglyza saxagliptin met the primary endpoint. Patients receiving once-daily 2.5 and 5 mg Onglyza plus TZD showed a decrease in adjusted mean change A1c from baseline of 0.7% and 0.9%, respectively, vs. 0.3% for TZD only (p<0.001 for both). In both the low...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >